|
| 37743194 | European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. | Eur Urol | 2024 |
| 37615760 | The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases. | Eur Radiol | 2024 |
| 36114082 | B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. | Eur Urol | 2023 |
| 37488446 | A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. | Br J Cancer | 2023 |
| 37750943 | Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement. | Br J Radiol | 2023 |
| 37660399 | Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases. | Br J Radiol | 2023 |
| 37844613 | Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. | Nature | 2023 |
| 37652207 | Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer. | Lab Invest | 2023 |
| 37788117 | Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response. | JNCI Cancer Spectr | 2023 |
| 37254225 | Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives. | Cancer Imaging | 2023 |
| 36964041 | Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]. | Eur Urol | 2023 |
| 37358356 | Development and Evaluation of Machine Learning in Whole-Body Magnetic Resonance Imaging for Detecting Metastases in Patients With Lung or Colon Cancer: A Diagnostic Test Accuracy Study. | Invest Radiol | 2023 |
| 34598790 | Imaging features of the evolving patterns of metastatic prostate cancer. | Clin Radiol | 2022 |
| 35384456 | A review on the added value of whole-body MRI in metastatic lobular breast cancer. | Eur Radiol | 2022 |
| 35672838 | Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer? | Cancer Imaging | 2022 |
| 35491356 | Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. | Eur Urol Oncol | 2022 |
| 35717027 | Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. | J Immunother Cancer | 2022 |
| 35656509 | Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice. | Front Oncol | 2022 |
| 35984704 | A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer. | Clin Cancer Res | 2022 |
| 35881184 | Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients. | Eur Radiol | 2022 |
| 36115298 | Deep-learned estimation of uncertainty in measurements of apparent diffusion coefficient from whole-body diffusion-weighted MRI. | Comput Biol Med | 2022 |
| 35092476 | Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. | Eur Radiol | 2022 |
| 34756755 | Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease. | Clin Oncol (R Coll Radiol) | 2022 |
| 33958296 | Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. | Clin Genitourin Cancer | 2021 |
| 35845288 | Whole body-diffusion weighted imaging for the assessment of treatment response in hairy cell leukaemia: A positive first step. | EJHaem | 2021 |
| 35665022 | A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. | J Immunother Precis Oncol | 2021 |
| 33685408 | Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. | BMC Cancer | 2021 |
| 33822745 | JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. | Cancer Res | 2021 |
| 33733812 | Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. | Br J Radiol | 2021 |
| 33549985 | Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience. | Cancer Treat Res Commun | 2021 |
| 34924031 | DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. | Cancer Imaging | 2021 |
| 34617028 | Accelerating Whole-Body Diffusion-weighted MRI with Deep Learning-based Denoising Image Filters. | Radiol Artif Intell | 2021 |
| 34753775 | HER3 Is an Actionable Target in Advanced Prostate Cancer. | Cancer Res | 2021 |
| 33934876 | Whole-body MRI: a practical guide for imaging patients with malignant bone disease. | Clin Radiol | 2021 |
| 34036765 | The emerging role of whole-body magnetic resonance imaging in advanced prostate cancer. | Minerva Urol Nephrol | 2021 |
| 31577852 | Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR. | J Pathol Clin Res | 2020 |
| 33854564 | Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phaseâ¿¿II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037). | Ther Adv Med Oncol | 2020 |
| 31874108 | Genomics of lethal prostate cancer at diagnosis and castration resistance. | J Clin Invest | 2020 |
| 31806540 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. | Lancet Oncol | 2020 |
| 33128873 | Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. | Lancet Oncol | 2020 |
| 33298007 | Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. | BMC Cancer | 2020 |
| 32741975 | Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. | Br J Cancer | 2020 |
| 32822545 | What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. | Br J Radiol | 2020 |
| 32653323 | Elucidating Durable Responses to Immune Checkpoint Inhibition. | Eur Urol | 2020 |
| 32332017 | Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. | Clin Cancer Res | 2020 |
| 32169873 | Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab. | J Immunother Cancer | 2020 |
| 32457842 | Noise-Corrected, Exponentially Weighted, Diffusion-Weighted MRI (niceDWI) Improves Image Signal Uniformity in Whole-Body Imaging of Metastatic Prostate Cancer. | Front Oncol | 2020 |
| 32568634 | Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. | J Clin Oncol | 2020 |
| 32532747 | Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers. | Cancer Discov | 2020 |
| 30340782 | Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. | Eur Urol | 2019 |